Verici Dx Plc (VRCI) ORD GBP0.001

- Add to watchlist
- Create an alert
- This stock can be held in a




Business summary
Verici Dx plc is an immuno-diagnostics development company that is focused on the kidney transplantation market. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. The Company's products include Clarava and Tuteva. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. The Company's subsidiary is Verici Dx Inc.
Contact details
Important dates
General stock information
- EPIC:
- VRCI
- ISIN:
- GB00BM8HZD43
- Market cap:
- £44.28 million
- Shares in issue:
- 170.32 million
- Sector:
- No specific Industry
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.